Test Results: Parkinson's Disease Pilot Study II
NOTE:
1. In all scales, the lower the number, the better the outcome.
2. N=6 per group
3. +/- delineates Standard Deviation
| Standard Test or Scale |
BASELINE |
END POINT
WEEK 8
|
% CHANGE |
p value |
PDQ-39 Summary Index (SI)
Quality of Life
|
|
|
|
|
| Treatment |
20.01 +/-12.26< |
11.61 +/-7.44 |
-42 |
p < .05 |
| Control |
24.52 +/-6.93 |
22.70 +/-6.84 |
-7 |
|
| PDQ-39 (Mobility) |
|
|
|
|
| Treatment |
25.0 +/-24.75 |
13.33 +/-13.48 |
-47 |
p < .05 |
| Control |
35.42 +/-12.49 |
33.33 +/-16.56 |
-6 |
|
PDQ-39 ADL
(Activities of Daily Living) |
|
|
|
|
| Treatment |
25.00 +/-18.07 |
9.03 +/-6.67 |
-64 |
p < .05 |
| Control |
22.92 +/-5.74 |
20.83 +/-6.97 |
-9 |
|
PDQ-39 BD
(Bodily Discomfort/Pain) |
|
|
|
|
| Treatment |
27.78 +/-15.52 |
19.45 +/-6.80 |
-30 |
p < .05 |
| Control |
22.22 +/-14.59 |
25.00 +/-20.41 |
+13 |
|
Beck Depression Inventory II
(Depression) |
|
|
|
|
| Treatment |
12.33 +/-4.76 |
6.6 +/-5.32 |
-47 |
p < .05 |
| Control |
12.17 +/-7.25 |
12.00 +/-4.94 |
-1 |
|
UPDRS II (ON)
Activities of Daily Living |
|
|
|
|
| Treatment |
9.83 +/-6.34 |
4.33 +/-4.08 |
-56 |
p < .05 |
| Control |
11.67 +/-4.27 |
8.33 +/-2.25 |
-28 |
|
| UPDRS III (ON) Motor |
|
|
|
|
| Treatment |
23.50 +/-12.99 |
14.00 +/-7.56 |
-40 |
p = .054 |
| Control |
29.67 +/-7.94 |
23.83 +/-11.44 |
-20 |
|
| FSS - Fatigue |
|
|
|
|
| Treatment |
34.33 +/-10.23 |
26.67 +/-9.29 |
-22 |
p = .125 |
| Control |
35.17 +/-8.93 |
33.33 +/-9.65 |
-5 |
|
Click Here to View the Test Battery for PARKINSON’S DISEASE PILOT STUDY II
PARKINSON’S DISEASE PILOT STUDY I
Title: Jacobson Resonator™ device: Efficacy of the Application of Magnetic Fields to the Treatment of Parkinson’s Disease. IRC # 07021-02
Primary Purpose of the Study:
- To gain a more formal idea - both qualitative and quantitative – of precisely how and to what extent the Resonator™ device may assist in alleviating the signs and symptoms of idiopathic Parkinson's disease when exercising greater control on the treated patient population and size and study outcome measures.
- To develop a treatment protocol with set output parameters that can effect improvement in Parkinson's disease signs and symptoms universally.
Design: non-randomized, non-blinded single (treatment only) group study.
Subject Demographics:
- Time frame: 2/9/07 – 5/5/07
- 13 subjects total: 9 females; 4 males
- All 13 were Caucasian
- Avg age: 62 years (SD: 13 yrs; Range: 47-82 yrs)
- Avg age of PD symptoms onset: 50.15 yrs (SD: 14.35 yrs; Range: 25-75 yrs)
- Avg age of PD diagnosis: 52.31 yrs (SD: 13.37 yrs; Range: 27-75 yrs)
- Avg length of time since PD symptom onset: 11.77 yrs (SD: 7.45 yrs; Range: 4-23 yrs)
Methodology: Treated with Resonator™ device for about 1.5 hours 3X per week for 3-5 weeks.
Outcome:
| Standard Test or Scale |
BASELINE |
3
WEEKS
|
% CHANGE |
| UPDRS II (ADL) |
13.92 +/- 4.59 |
6.77 +/- 3.42 |
-51% |
| UPDRS III (motor) |
32.46 +/- 10.09 |
21.08 +/- 8.83 |
-35% |
| PDQ-39-SI |
24.75 +/- 12.85 |
18.81 +/- 14.47 |
-24% |
Notable improvements were also reported in the following areas:
- Decreased fatigue/increased energy.
- Improvement in the quality and quantity of sleep.
- Ability to return and/or increase participation level in prior activities such as golf and driving.
Subjects were evaluated weekly post-treatment until their PD symptoms had returned to near pre-treatment levels. For almost all subjects, improvement in symptoms was substantially sustained for three weeks after treatment end before starting to diminish.
OTHER DISEASES/CONDITIONS
Please click on different studies in the Pipeline Chart to view Posterboard Presentations.
